Structure Therapeutics Cash Flow Statement
NASDAQ: GPCRHealth CareBiotechnology: Pharmaceutical PreparationsUSD
25.54-0.13 (-0.51%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Structure Therapeutics free cash flow
In fiscal 2025, Structure Therapeutics generated -$222.2 million of operating cash flow and spent $3.6 million on capital expenditures. That left free cash flow of -$225.8 million.
Summary generated from market data by MetaCap's automated system. Methodology
Structure Therapeutics cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 |
|---|---|---|---|---|
| Net Income | -141.20M | -122.53M | -89.62M | -51.32M |
| Net Income growth (YoY) | — | — | — | — |
| Depreciation & Amortization | 1.33M | 992.00K | 295.00K | 277.00K |
| Stock-Based Compensation | 28.99M | 18.79M | 8.19M | 2.51M |
| Change in Working Capital | -11.65M | 1.90M | -4.90M | 1.85M |
| Operating Cash Flow | -222.20M | -116.64M | -79.49M | -46.12M |
| Capital Expenditures | -3.61M | -1.29M | -2.17M | -155.00K |
| Investing Cash Flow | 89.80M | -358.91M | -268.34M | -62.11M |
| Financing Cash Flow | 762.52M | 515.26M | 451.53M | 29.01M |
| Net Change in Cash | 630.11M | 39.72M | 103.70M | -79.21M |
| Free Cash Flow | -225.81M | -117.93M | -81.66M | -46.27M |
This table shows 4 annual periods of Structure Therapeutics's cash flow statement, from FY 2025 back to FY 2022, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow GPCR's reporting calendar. What is a cash flow statement?